The Trump administration is not exactly full of fans of legal cannabis.
Attorney General Jeff Sessions' opposition is well known. "Good people don't smoke marijuana," he said in April 2016, while still a senator from Alabama. And it's only gotten worse from there.
Vice President Mike Pence signed a law during his time as Indiana governor that would land you with a $1,000 fine and up to six months' jail time if found in possession of the drug. And you know he has the president's ear.
That's why what comes next is so shocking: President Donald Trump plans to back medical marijuana after the midterm elections.
Or at least that's what U.S. Rep. Dana Rohrabacher (R-CA) is saying.
Rohrabacher, a longtime proponent of legalization, said in a recent interview on Fox Business that plans for a massive cannabis reform have been a hot topic of discussion among Trump's inner circle. He's talking the sort of reform that could end cannabis prohibition on a federal level.
At the very least, Rohrabacher says, the president plans to keep his promise not to interfere in states' marijuana policies.
"It could be as early as spring of 2019," Rohrabacher claims.
Despite the hype, I'm not overly excited.
As much as I hate to do so, it's worth quoting House Minority Leader Nancy Pelosi here.
"I don't know where the president is on any of this," she said recently. "So any decision about how we go forward would have to reflect where we can get the result."
In other words, while medical marijuana seems to have majority support on both sides of the aisle, any sort of nationwide legalization is just talk so far.
Rumors – and little more than that.
However, while the windbags in Washington haggle over who-knows-what, Canada has its legislation in place and is less than one day away from full legalization. Tomorrow, Oct. 17, dozens of adult-use, recreational dispensaries will open in several provinces – and nationwide online ordering will start up.
That's why, instead of investing on hope here at home, savvy investors are looking north. In the next year, Canada's cannabis markets are projected to swell up to $8.7 billion. And some analysts think they'll quickly bust the $20 billion mark.
As we always say... When laws pass, stocks soar. And right now, no laws are passing in the United States – at least not on the national level.
But the clock is ticking. There's less than 48 hours until this market opens up. By then, it could be too late to get in on the massive gains.
I've put together an exclusive briefing that starts showing exactly which pot stocks could soar – and which could fail spectacularly – so you know where to put your money to watch it grow.
Readers who act now could be sitting on $2 million by this time next year.
All you have to do is click here.
The post Follow the Legal Cannabis Money - not the Hype appeared first on Strategic Tech Investor | Michael A. Robinson.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.